MLTX
MoonLake Immunotherapeutics
11.40$
-0.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | – | – | 100.0% | – | – | – | – | – | – | – | |
| – | 16.7% | 115.6% | – | – | 50.0% | – | – | – | – | – | – | – | |
| – | 83.3% | -115.6% | – | – | 50.0% | – | – | – | – | – | – | – | |
| – | 41,026.4% | 65,933.7% | – | – | 39,626.5% | – | – | – | – | – | – | – | |
| – | 35,115.5% | 34,481.7% | – | – | 9,053.3% | – | – | – | – | – | – | – | |
| – | 76,141.9% | 100,415.4% | – | – | 48,679.8% | – | – | – | – | – | – | – | |
| – | -76,141.9% | -100,415.4% | – | – | -48,679.8% | – | – | – | – | – | – | – | |
| – | 19,949.9% | 19,949.9% | – | – | – | – | – | – | – | – | – | – | |
| – | -39,736.0% | -70,447.9% | – | – | -45,512.6% | – | – | – | – | – | – | – | |
| – | 224.5% | 354.6% | – | – | 40.4% | – | – | – | – | – | – | – | |
| – | -37,679.0% | -69,272.5% | – | – | -44,776.2% | – | – | – | – | – | – | – | |
| – | -39,719.3% | -68,786.1% | – | – | -44,234.9% | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.